Managing Editor, Senior Health Care News Editor
Jonathan Block is the Managing Editor and Senior Health Care News Editor at Seeking Alpha. With a Master's in Public Health from CUNY Graduate School of Public Health, he brings expertise in the healthcare sector to his writing. His articles cover a wide range of topics, including stock analysis, market trends, and industry news.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jonathan Block's coverage focuses on investment analysis, press releases, and data citations related to sales & marketing and automotive industries. He would likely be interested in pitches that provide in-depth analysis of stock performance, company news, and market trends within these sectors.
Given his focus on investment analysis and citation of data, Jonathan may find value in pitches from financial experts who can offer unique insights into the potential impact of various factors on stock performance or industry trends.
While Jonathan does not have a specific geographic focus mentioned but given the nature of his articles focusing mainly on companies listed in US stock exchanges (NASDAQ: HAS; NYSE: MTN), it is safe to assume he has an interest primarily in the US market.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jonathan Block
surgeon Marty Makary is seen as the top contender for FDA commissioner in the next Trump administration. Read more here.
By: Jonathan Block
Morgan Stanley has initiated coverage of Apellis Pharmaceuticals ( NASDAQ: APLS ) at equal-weight saying that the next phase of growth in the geographic atrophy (GA) market will be slower than the prior one.
Trump Media & Technology Group (DJT) plans to establish a cryptocurrency payment platform named TRUTHFI, offering various financial services.
By: Jonathan Block
HIM & Hers Health stock rises after federal court closes case on FDA's GLP-1 tirzepatide shortage determination. Read more here.
By: Jonathan Block
Miplyffa, first medication approved for Niemann-Pick disease type C, now available from Zevra Therapeutics. Read more here.
By: Jonathan Block
B Riley is bullish on Viking Therapeutics, citing potential for obesity treatment to disrupt market. Read more here.
By: Jonathan Block
Sanofi challenges HHS' 340B program by requiring hospitals to provide claims data before receiving discounts on drugs, following in J&J and Eli Lilly's footsteps. Read more here.
By: Jonathan Block
Moderna rises 8% as management downplays concerns over potential HHS leadership under RFK Jr. Read more here.
Omeros ( NASDAQ: OMER ) is up ~22% in Friday trading after stating that based on recent feedback from the U.S.
By: Jonathan Block
Robinhood Markets ( NASDAQ: HOOD ) Chief Legal Officer Dan Gallagher is out of the running for the SEC chairman post under President-Elect Donald Trump after saying he's not interested.
(833) 317-6278 
